Cargando…

Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins

Biologics have emerged as a powerful and diverse class of molecular and cell-based therapies that are capable of replacing enzymes, editing genomes, targeting tumors, and more. As this complex array of tools arises a distinct set of challenges is rarely encountered in the development of small molecu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, Alison, Manoli, Hugh, Jaw, Stacey, Frutoz, Kimberley, Epstein, Alan L., Khawli, Leslie A., Theil, Frank-Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2016
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4992793/ https://www.ncbi.nlm.nih.gov/pubmed/27579329 http://dx.doi.org/10.1155/2016/2342187

Ejemplares similares

Recent Advances in Assessing Immunogenicity of Therapeutic Proteins: Impact on Biotherapeutic Development
por: Lu, Yanmei, et al.
Publicado: (2016)

Principles of N-Linked Glycosylation Variations of IgG-Based Therapeutics: Pharmacokinetic and Functional Considerations
por: Boune, Souad, et al.
Publicado: (2020)

Brain Disposition of Antibody-Based Therapeutics: Dogma, Approaches and Perspectives
por: Kouhi, Aida, et al.
Publicado: (2021)

Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection
por: Venisse, Nicolas, et al.
Publicado: (2020)

Ceftobiprole: pharmacokinetics and PK/PD profile
por: Azanza Perea, José Ramón, et al.
Publicado: (2019)

In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis
por: Xiao, Xia, et al.
Publicado: (2015)

Antibody targeted CpG for the immunotherapy of solid tumors
por: Epstein, Alan L, et al.
Publicado: (2015)

In vivo Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Establishment of the PK/PD Cutoff of Florfenicol Against Pasteurella multocida in Ducks
por: Xiao, Xia, et al.
Publicado: (2021)

Blood‐Based Biomarkers of Quinpirole Pharmacology: Cluster‐Based PK/PD and Metabolomics to Unravel the Underlying Dynamics in Rat Plasma and Brain
por: van den Brink, Willem J., et al.
Publicado: (2019)

Epidemiological and PK/PD cutoff values determination and PK/PD-based dose assessment of gamithromycin against Haemophilus parasuis in piglets
por: Zhou, Yu-Feng, et al.
Publicado: (2020)

Joint analysis of PK and immunogenicity outcomes using factorization model − a powerful approach for PK similarity study
por: Haliduola, Halimu N., et al.
Publicado: (2022)

PK/PD analysis of trazodone and gabapentin in neuropathic pain rodent models: Translational PK‐PD modeling from nonclinical to clinical development
por: Oggianu, Laura, et al.
Publicado: (2023)

Population PK/PD modelling of meropenem in preterm newborns based on therapeutic drug monitoring data
por: Zyryanov, Sergey, et al.
Publicado: (2023)

The PK/PD Interactions of Doxycycline against Mycoplasma gallisepticum
por: Zhang, Nan, et al.
Publicado: (2016)

The Role of PK/PD Analysis in the Development and Evaluation of Antimicrobials
por: Rodríguez-Gascón, Alicia, et al.
Publicado: (2021)

Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development
por: Tibbitts, Jay, et al.
Publicado: (2015)

Pharmacokinetics (PK), pharmacodynamics (PD), and PK-PD integration of ceftiofur after a single intravenous, subcutaneous and subcutaneous-LA administration in lactating goats
por: Fernández-Varón, Emilio, et al.
Publicado: (2016)

1321. Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J, et al.
Publicado: (2020)

Population PK and Semimechanistic PK/PD Modeling and Simulation of Relugolix Effects on Testosterone Suppression in Men with Prostate Cancer
por: Lee, Tien‐Yi, et al.
Publicado: (2022)

Immunomonitoring of Tacrolimus in Healthy Volunteers: The First Step from PK- to PD-Based Therapeutic Drug Monitoring?
por: in ‘t Veld, Aliede E., et al.
Publicado: (2019)

Pharmacokinetics (PK), Pharmacodynamics (PD) and Integrated PK/PD Modeling of a Novel Long Acting FGF21 Clinical Candidate PF-05231023 in Diet-Induced Obese and Leptin-Deficient Obese Mice
por: Weng, Yan, et al.
Publicado: (2015)

PK/PD modeling supports the dose-escalation decision in VIKING
por: Lovern, M, et al.
Publicado: (2010)

The role of population PK–PD modelling in paediatric clinical research
por: De Cock, Roosmarijn F. W., et al.
Publicado: (2010)

PK/PD analysis of biapenem in patients undergoing continuous hemodiafiltration
por: Akashita, Gaku, et al.
Publicado: (2015)

PK-PD Analysis of Marbofloxacin against Streptococcus suis in Pigs
por: Lei, Zhixin, et al.
Publicado: (2017)

The PK/PD Integration and Resistance of Tilmicosin against Mycoplasma hyopneumoniae
por: Huang, Zilong, et al.
Publicado: (2020)

S17.3 PK/PD in the treatment of hospital-acquired pneumonia
Publicado: (2005)

Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models
por: Zhang, Longfei, et al.
Publicado: (2022)

Combined PK/PD Index May Be a More Appropriate PK/PD Index for Cefoperazone/Sulbactam against Acinetobacter baumannii in Patients with Hospital-Acquired Pneumonia
por: Zhou, Yingjie, et al.
Publicado: (2022)

Model‐Informed Drug Development for Antimicrobials: Translational PK and PK/PD Modeling to Predict an Efficacious Human Dose for Apramycin
por: Sou, Tomás, et al.
Publicado: (2020)

Research on the mechanism of drug–drug interaction between salvianolate injection and aspirin based on the metabolic enzyme and PK-PD model: study protocol for a PK-PD trial
por: Zhang, Wantong, et al.
Publicado: (2018)

Prediction of Clinical Irrelevance of PK Differences in Atorvastatin Using PK/PD Models Derived From Literature-Based Meta-Analyses
por: Vargo, R, et al.
Publicado: (2014)

1550. PK-PD Relationship and PK Driver of Efficacy of the Novel Antibacterial Lysin Exebacase (CF-301) in Pre-Clinical Models
por: Ghahramani, Parviz, et al.
Publicado: (2019)

Increasing interest in PK and PD studies has many advantages for anesthesiologists
por: Woo, Young-Cheol
Publicado: (2011)

Traditional PK-PD Indices for Efficacy – Can We Do Better?
por: Lakota, Elizabeth A, et al.
Publicado: (2017)

Re-Assessing PK/PD Issues for Oral Protein and Peptide Delivery
por: Mrsny, Randall J., et al.
Publicado: (2021)

P267 Candida in the biliary tract: extrapolative PK PD considerations
por: Rege, Sujata, et al.
Publicado: (2022)

Editorial: Pharmacokinetics, pharmacodynamics (PK/PD) of antibiotics: A reality check
por: Zeitlinger, Markus, et al.
Publicado: (2023)

Meropenem PK/PD Variability and Renal Function: “We Go Together”
por: Angelini, Jacopo, et al.
Publicado: (2023)

DNA-PK as an Emerging Therapeutic Target in Cancer
por: Mohiuddin, Ismail S., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jn9anslb4f03ick9abifd3bls2